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Abstract: Neuronal miRNA dysregulation may have a role in the pathophysiology of Alzheimer’s
disease (AD). miRNA(miR)-124 is largely abundant and a critical player in many neuronal functions.
However, the lack of models reliably recapitulating AD pathophysiology hampers our understanding
of miR-124’s role in the disease. Using the classical human SH-SY5Y-APP695 Swedish neuroblastoma
cells (SH-SWE) and the PSEN1 mutant iPSC-derived neurons (iNEU-PSEN), we observed a sustained
upregulation of miR-124/miR-125b/miR-21, but only miR-124 was consistently shuttled into their
exosomes. The miR-124 mimic reduced APP gene expression in both AD models. While miR-124
mimic in SH-SWE neurons led to neurite outgrowth, mitochondria activation and small Aβ oligomer
reduction, in iNEU-PSEN cells it diminished Tau phosphorylation, whereas miR-124 inhibitor de-
creased dendritic spine density. In exosomes, cellular transfection with the mimic predominantly
downregulated miR-125b/miR-21/miR-146a/miR-155. The miR-124 inhibitor upregulated miR-146a
in the two experimental cell models, while it led to distinct miRNA signatures in cells and exosomes.
In sum, though miR-124 function may be dependent on the neuronal AD model, data indicate
that keeping miR-124 level strictly controlled is crucial for proper neuronal function. Moreover,
the iNEU-PSEN cellular model stands out as a useful tool for AD mechanistic studies and perhaps
for the development of personalized therapeutic strategies.
Keywords: Alzheimer’s disease (AD); cell experimental models; inflammatory-associated miRNAs;
iPSC-derived neurons; miR-124-3p modulation; neuronal dysfunction; neuropathological hallmarks
of AD; paracrine signaling; secretome; small extracellular vesicles (exosomes)
1. Introduction
Neuronal miRNA (miR)-124 is one of the most abundant miRNAs in the brain [1].
It was firstly shown to control the choice between neuronal and astrocyte differentia-
tion [2], as well as to promote neuronal differentiation [3] and neurite outgrowth [4].
However, electrophysiological studies showed that miR-124 also constrains synaptic plas-
ticity [5]. Though not found in macrophages, miR-124 is expressed in microglia, where it
was associated to their deactivation and suppression of experimental autoimmune en-
cephalomyelitis [6]. Interestingly, miR-124 was referred to ameliorate the motor symptoms
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in Parkinson’s disease and to have pro-neurogenic potential when loaded in polymeric
nanoparticles [7]. By using SH-SY5Y neuroblastoma cells, An et al. demonstrated that
miR-124 is a potent negative regulator of β-site amyloid precursor protein-cleaving enzyme
(BACE1) and that it may be involved in Alzheimer’s disease (AD) pathology, consider-
ing its reduced expression in AD sporadic patients [8]. In contrast, a marked miR-124
upregulation in the hippocampus and temporal cortex was observed in AD patients and
in the Tg2576 transgenic mice, where it was associated to an elevation of the amyloid-β
(Aβ) peptide 1–42 [9]. These authors identified the miR-124/PTPN1 pathway as a critical
mediator of synaptic dysfunction and memory loss in AD. Therefore, the results about the
beneficial or harmful effects of miR-124 expression levels in AD, which may result from
the different models, mutations or disease stages used in such studies, are controversial.
When we assessed miR-124 expression in human hippocampal homogenates from healthy
individuals and from AD patients in Braak stages II, III, IV and V/VI, we only observed a
significant elevation of miR-124 in stage III [10]. Such a finding may relate to a potential
defensive mechanism that is induced at disease middle stages and later disappears due
to neuronal demise. In contrast, the role of miR-124 in amyotrophic lateral sclerosis (ALS)
seems to be linked to pathological processes. In conformity, we found that miR-124 eleva-
tion in the mutated SOD1 (mSOD1) motor neurons was associated to neurodegeneration
and paracrine signaling dysregulation in N9 microglia and spinal organotypic cultures
from the transgenic mSOD1 mice [11]. Besides the mitochondrial accumulation of TAR
DNA-binding protein 43 (TDP-43) that may occur in AD and ALS [12], the diseases have
different pathological signatures. AD affects multiple brain regions critical to learning
and memory and the most common cellular and molecular hallmarks are extracellular Aβ
plaques and neurofibrillary tangles of hyperphosphorylated Tau protein [13]. As for ALS,
the disease specifically affects upper and lower motor neurons leading to neuromuscular
junction instability and distal axonal degeneration [14].
Using an in vitro model of AD, we previously observed an elevation of miR-124 in
the dopaminergic SH-SY5Y neuroblastoma cell line expressing the APP695 Swedish mutant
gene (SH-SWE), as compared to their naïve SH-SY5Y (SH-WT) cells [15]. These cells that
mimic the usual neuronal morphology and neurite outgrowth showed, after differentiation
with the retinoic acid (RA) [16], an overexpression of several reactive (e.g., S100B) and
inflammatory transcripts (e.g., HMGB1, TNF-α), as well as the release of Aβ1-40 when
expressing the mutated APP [15]. However, we must also consider that RA is known to
affect cell susceptibility to neurotoxins by inducing higher immunologic tolerance and
lower neurotoxic responses [17]. In all ways, the expression of a variety of markers of
mature neurons makes SH-SY5Y cells useful to investigate several diseases, including
AD, and to obtain accurate results that may be translated into in vivo models [18]. In fact,
the evaluation of RA-maturated SH-SY5Y cells by proteomic analysis revealed upregulated
proteins that were involved in neuritogenesis [19]. Transfection with the APP695 Swedish
mutant gene did not affect cell morphology and resulted in neurotoxicity [20]. The model
is then considered useful to study AD pathogenesis [21] and to test novel therapeutic
strategies [22], but the modeling of AD with induced pluripotent stem cell (iPSC)-derived
neurons (iNeurons) brought new potentials in the recapitulation of molecular mechanisms
of AD. Indeed, iNeurons better mimic the in vivo conditions and hold great promise to
assess neurotoxic mechanisms, though they show differences in spontaneous neuronal
activity [23–25]. These cells have even been proposed for AD treatment by transplanta-
tion [26]. A study using iPSC lines generated from familiar AD patients revealed increased
Aβ42:40 in all, but quantitatively and qualitatively divergent Aβ secretomes, and that
distinct presenilin 1 (PSEN1) mutations caused different alterations, altogether culminat-
ing in the reduction in γ-secretase carboxypeptidase-like activity [27]. Dysregulation of
endocytosis-associated genes and early endosome enlargement were observed in human
iPSC lines carrying APP and/or PSEN1 mutations [28]. Nonetheless, experimental vari-
ations between studies associated to cellular heterogeneities, as well as to transcript and
protein abundance, may occur with iPSCs, and the maturity of the generated iNeurons
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may fail in reproducing the biological age at disease onset [29]. Interestingly, despite the
evidence that miR-124 induces neuronal differentiation and functional maturation [30],
to the best of our knowledge there are no studies addressing the expression levels of
miR-124 in iNeurons from AD iPSCs.
Considering that experimental models of AD are critical to advance knowledge on the
underlying pathological mechanisms and that all have limitations [31], we here used two
different approaches to gain insight into the potential contribution of neuronal miR-124
expression levels in AD-associated pathological mechanisms. We used the classical SH-WT
and the SH-SWE cell lines based on our previous experience with these models [15], and the
advanced model of dopaminergic midbrain iNeurons generated from iPSCs derived from a
healthy individual (iNEU-WT) and a patient carrying a deletion in the exon 9 of the PSEN1
gene (iNEU-PSEN). The original iPSCs were already characterized, described, and used
after differentiation into astrocytes to show associated pathological features [32], and into
microglia to evidence a disparate phenotype relatively to those obtained from patients with
the APP-SWE mutation and with the apolipoprotein E4 (APOE4) variant [33]. Therefore,
considering the controversy around the role that miR-124 may have on the AD onset and
progression and the unique opportunity to have these two different AD experimental
models, we decided to transfect both cell lines with either the miR-124 inhibitor or the
miR-124 mimic to reduce and increase its expression levels, respectively, and to investigate
the consequences on neuronal dynamics, predictive function and paracrine signaling.
We first assessed the basal miR-124 expression levels, together with other miRNAs
associated to neuroinflammation (inflamma-miRNAs), in such different cell experimental
models and in their small extracellular vesicles that will be designed here as exosomes.
Mature miRNAs are derived from a duplex precursor, where the -5p strand or “guide”
is preferentially incorporated into the RNA-induced silencing complex and the comple-
mentary -3p strand or “passenger” is believed to be more prone to being degraded [10].
Here, we evaluated the following specific strands: miR-124-3p (the most assessed in the
literature), miR-21-5p, miR-125b-5p, miR-155-5p and miR-146a-5p. They will be used
from now on without specifying the strand unless required. Consequences of miR-124 up-
and downregulation were evaluated on dendrite outgrowth and mitochondria dynamics,
spine density, APP and Aβ processing, Tau phosphorylation and miRNA content in the
secretome (either as free species or as part of exosomal cargo).
Data show the existence of similar and dissimilar pathological events in the two AD
neuronal models used, which help to further understand the AD-associated disparate re-
sults on miR-124 in the literature. Globally, we provide evidence that miR-124 upregulation
is associated to the prevention of some AD-associated pathological mechanisms and the
propagation of inflamma-miRNAs mediated by exosomes, once such effects disappeared
by miR-124 downregulation. Our results also highlight the importance of stratifying pa-
tients toward more effective and patient-centered care using miR-124 as a biomarker and
therapeutic target in AD pathology.
2. Materials and Methods
2.1. Culture and Differentiation of Human SH-WT and SH-SWE Cells
SH-WT (naïve) and SH-SWE (transfected with human APP695) cells were a gift from
Professor Anthony Turner. Cells that were routinely tested for mycoplasma contamination
were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) (Gibco, Thermo Fisher
Scientific, Waltham, MA, USA), supplemented with 10% Fetal Bovine Serum (FBS) and 2%
AB/AM, in T75 flasks. Briefly, cells were maintained in a humidified atmosphere at 5%
CO2, 37 ◦C, and seeded into 12-well plates coated with poly-D-lysine (100 µg/mL, Sigma-
Aldrich, St. Louis, MO, USA) and laminin (4 µg/mL, Gibco, Thermo Fisher Scientific,
Waltham, MA, USA) at a final concentration of 5 × 104 cells per well. To induce neuronal
differentiation, we used 10 µM of RA and the medium was changed every day for 7 days,
as previously described [34] and currently implemented in our laboratory [15].
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2.2. Culture of Human iPSCs, Neuronal Differentiation and Cell Maturation
iPSCs, generated from a female AD patient carrying PSEN1 exon 9 deletion (PSEN1∆E9
mutation) and from a healthy female control, were kindly provided by Dr J. Koistinaho
(from the University of Helsinki; in the past, from the University of Eastern Finland), un-
der the JPco-fuND 2015 project MADGIC, covered by Material Transfer Agreement, and in
close collaboration with the project team partners Dr F. Edenhofer (from the University
of Innsbruck) and Dr T. Malm (from the University of Eastern Finland). iPSC lines were
generated after approval of the committee on Research Ethics of Northern Savo Hospital
district (123/2016) and written consent from the subjects. Demographic information of
each iPSC-line is summarized in Supplementary Table S1. Full characterization in terms of
genetic stability and pluripotency markers of such iPSCs was previously published in stud-
ies using their differentiation into astrocytes (iAstrocytes) and microglia (iMicroglia) for
characterization of AD-associated glial aberrancies [32,33]. In our laboratory, iPSCs were
differentiated into the midbrain dopaminergic neurons iNEU-WT (from a healthy female
control) and iNEU-PSEN (from a female pre-symptomatic AD patient), following described
and established protocols [32,35], with minor modifications, as schematized in Supplemen-
tary Figure S1. In brief, iPSCs were grown on Matrigel-coated (Corning, Corning, NY, USA)
plates in Essential 8 (E8) medium and passaged with 0.5 mM EDTA. Freshly passaged
cells were cultured with 5 mM Y-27632 ROCK inhibitor (Selleckchem, Houston, TX, USA).
Differentiation started by changing to neural differentiation medium (NDM) consisting
of DMEM/F12 and Neurobasal (1:1), 1% B27 without vitamin A, 0.5% N2, 1% Glutamax,
and 0.5% penicillin/streptomycin (50 IU/50 mg/mL) (all from Invitrogen, Waltham, MA,
USA), supplemented with dual SMAD inhibitors 10 mM SB431542 (Sigma) and 200 nM
LDN193189 (Selleckchem). Medium was changed daily for 12 days, until rosette-like
structures started to emerge (Supplementary Figure S2). Cells were then cultured in NDM
supplemented with 20 ng/mL basic fibroblast growth factor (bFGF) for 2–3 days to expand
the rosettes. Areas with rosettes were mechanically lifted and cultured in suspension on
ultra-low attachment plates (Corning) in NDM for 2 days to allow for neural progenitor
sphere (NPS) formation. Then, spheres were maintained in NDM supplemented with
10 ng/mL bFGF and 10 ng/mL epidermal growth factor (EGF) (Peprotech, Rocky Hill, NJ,
USA) for 1 month. Medium was changed every 2–3 days and spheres were split manually
every week. For neuronal maturation, spheres were dissociated with Accutase (STEM-
CELL Technologies, Vancouver, BC, Canada) and plated on Poly-L-ornithine (20 µg/mL) +
Laminin (10 µg/mL)-coated dishes and differentiated using Neuron Induction Medium
(NIM) consisting of DMEM-F12 and Neurobasal (1:1), 1% N2, 2% B27 without vitamin
A, 1% L-Glutamax, and 0.5% penicillin/streptomycin (50 IU/50 mg/mL) (all from In-
vitrogen) supplemented with 20 ng/mL of neuronal BDNF and GDNF growth factors
(Peprotech), during 1 month prior to experiments. Neuronal differentiation and maturation
were confirmed by monitoring Tau, microtubule-associated protein MAP-2 and F-actin
immunostaining at week 11 (Supplementary Figure S3), followed by a deep look at synap-
tic dynamics by the immunofluorescence of pre-synaptic SV-2 and synapsin-1 markers,
together with the post-synaptic PSD-95 protein.
2.3. Isolation of Exosomes from the Cell Secretome
Exosomes were isolated by differential ultracentrifugation from the cell secretomes,
as we described [15,36]. Secretomes were obtained from the differentiated SH-WT/SH-
SWE cells and iNEU-WT/iNEU-PSEN cells, either untreated or after miR-124 modulation,
as described in Section 2.7. Equal volumes of cell media were promptly centrifuged at
1000× g for 10 min, to pellet cell debris. The supernatants were transferred into new tubes
and centrifuged at 16,000× g for 1 h, to pellet and discard the large extracellular vesicles,
usually denominated as microvesicles. The remaining supernatant was filtered using a
0.22 µm pore size membrane and centrifuged at 100,000× g for 2 h, using the Ultra L-XP100
centrifuge (Beckman Coulter, Brea, CA, USA) to isolate the exosomes. The pellet was
resuspended/washed in phosphate-buffered saline (PBS) and centrifuged once again at
Cells 2021, 10, 2424 5 of 27
100,000× g for 2 h. To evaluate miRNA content, pellets were then suspended in 200 µL lysis
buffer for RNA extraction with the miRCURY Isolation Kit-Cell (Exiqon, Gill StreetWoburn,
MA, USA). For protein extraction, pellets were resuspended in 50 µL Cell Lysis buffer
(Cell Signaling, Danvers, MA, USA), transferred into microtubes, snap-frozen and stored
at −80 ◦C until further quantification/analysis. For Transmission Electron Microscopy
(TEM), freshly isolated exosomes were resuspended and kept in ice-cold PBS for 1–2 days
until analysis.
2.4. Characterization of Exosomes for Morphology, Protein Markers, Concentration and Size
Distribution
Exosome morphology was assessed by TEM, using equal volumes of exosome sus-
pensions that were dried onto freshly ‘glow discharged’ 300 mesh formvar/carbon-coated
TEM grids (Ted Pella, Redding, CA, USA), negatively stained with 2% aqueous uracyl
acetate and observed under a TEM with a JEOL JEM 1400 microscope (JEOL Ltd., Tokyo,
Japan) at an accelerating voltage of 120 kV. Images were digitally recorded using a Gatan
SC 1100 ORIUS CCD camera (Gatan Inc., Warrendale, PA, USA). Round cup-shaped struc-
tures, ranging from 50 to 200 nm size were considered exosomes. Exosomes were also
characterized by the presence of ALIX, CD63 and flotillin proteins that are usually present
in these small extracellular vesicles. The presence of such exosomal markers was evaluated
by Western blot. Exosome samples were processed for protein extraction and quantification,
as described below. Since differences in the total protein content were detected in samples
collected from different cell models (Supplementary Table S2), the same protein amount
(30 µg) was used in every condition.
Concentration and size of exosomes were evaluated by Nanoparticle tracking assay
(NTA) using the Nanosight (model LM10-HSBF, Malvern Instruments, Malvern, UK).
Samples were injected into the system under controlled flow using a NanoSight syringe
pump and integrated scripting control system. Five different videos up to 60 s long were
made and particle movement was analyzed by NTA-software (version 3.1).
2.5. Protein Quantification and Western Blot
Concentration of proteins was determined by using the BCA Protein Assay Kit (Pierce,
Biotechnology, Waltham, MA, USA). Samples (30 µg of exosomes, 40 µg of SH-WT or
SH-SWE cells and 20 µg of iNEU-WT and iNEU-PSEN cells) were separated on Tris-Tricine
gel, transferred into nitrocellulose membranes (Amersham, Health, Buckinghamshire,
United Kingdom) and incubated in blocking buffer (5% (w/v) non-fat dried milk in Tween
20 (0.1%) tween-tris buffer saline (T-TBS)) for 1 h at room temperature. Membranes
were incubated at 4 ◦C overnight with primary antibodies: mouse anti-ALIX (1:1000,
Cell Signaling); goat anti-CD63 (1:1000, Santa Cruz Biotechnology, Dallas, TX, USA); mouse
anti-flotilin-1 (1:1000, BD Biosciences, Franklin Lakes, NJ, USA); mouse anti-amyloid β
(1:1000, Merck Millipore, Burlington, MA, USA); rabbit anti-phospho-Tau (Ser404) (1:1000,
Cell Signaling); rabbit anti-Tau (1:1000, Synaptic Systems, Goettingen, Germany); and
mouse anti-β-actin (1:2000, Sigma Aldrich, St. Louis, MO, USA). Each antibody was diluted
in blocking buffer, followed by incubation with the respective secondary antibodies for
1 h at room temperature, using HRP-conjugated goat anti-mouse (1:2000), rabbit anti-goat
(1:2000), and goat-anti-rabbit (1:2000), all from Santa Cruz Biotechnology. WesternBright
Sirius (Advansta, San Jose, CA, USA) was used as the chemiluminescent substrate and
the densitometric analysis of protein bands obtained with the ChemiDoc Imaging System
(Bio-Rad, Hercules, CA, USA). Relative intensity of protein bands was estimated using the
Bio-Rad Image Lab analysis software (Bio-Rad).
2.6. RNA Extraction and RT-qPCR
Total RNA was extracted from differentiated SH-WT/SH-SWE and iNEU-WT/iNEU-
PSEN cells, using TRIzol® reagent (LifeTechnologies), according to manufacturer’s in-
structions. Total RNA (enriched in miRNAs) from the exosomes was extracted using the
miRCURYTM LNATM Universal RT miRNA PCR kit (Qiagen, Venlo, The Netherlands).
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Quantification was performed with Nanodrop® ND-100 Spectrophotometer (NanoDrop
Technologies, Wilmington, DE, USA). For miRNA determination, equal amounts of RNA
were reverse transcribed into cDNA using the Universal cDNA Synthesis Kit (Qiagen).
Then, miRNA expression was determined by Real-Time Quantitative Polymerase Chain
Reaction (RT-qPCR) using the miRCURY LNATM Universal RT miRNA PCR kit (Qia-
gen). For mRNA determination, same amounts of total RNA were reverse transcribed
into cDNA using the GRS cDNA Synthesis Master Mix kit (GRiSP, Porto, Portugal) and
RT-qPCR was performed using Xpert Fast Sybr Blue (GRiSP) as master mix with specific
predesigned primers (Supplementary Table S3). Both miRNA and mRNA RT-qPCR were
run on QuantStudio 7 Flex RT-PCR System (Applied Biosystems, Waltham, MA, USA).
Running conditions for miRNAs consisted of polymerase activation/denaturation and
well-factor determination at 95 ◦C for 10 min, followed by 50 amplification cycles at 95 ◦C
for 10 s and 60 ◦C for 1 min (ramp-rate 1.6 ◦C/s). Running conditions for mRNA deter-
mination were 50 ◦C for 2 min followed by 95 ◦C for 2 min, 40 cycles at 95 ◦C for 5 s and
62 ◦C for 30 s. Melt-curve analysis was performed after amplification, and the specificity
of PCR products was confirmed. Expression data of at least four independent experi-
ments were processed using the 2−∆∆CT method with the internal control glyceraldehyde
3-phosphate dehydrogenase (GAPDH) for mRNA and that of U6 for miRNA, together
with the exogenous control Spike-in dataset. The results were expressed as fold change.
2.7. Modulation of miR-124 Levels in Neuroblastoma and iPSC-Derived Neurons
Differentiated SH-WT/SH-SWE cells and iNEU-WT/iNEU-PSEN cells were changed
to Optimem medium (Gibco, Thermo Fisher Scientific, Waltham, MA, USA) and transfected
with pre-miR-124-3p (mimic) and anti-miR-124-3p (inhibitor) (Ambion, Austin, TX, USA),
each at 15 nM/well and cultured overnight. Mock transfected and negative controls (Scram-
ble sequence provided by Qiagen) for both mimic and inhibitor were performed in parallel,
using the same concentrations and conditions. Transfection agent (X-tremeGENE—Sigma
Aldrich) was equally applied in each circumstance. Since we observed that mock and
negative control produced very similar results, only mock control data will be presented in
subsequent assays. SH-SWE cells were changed to FBS-free media, while iNEU-PSEN and
iNEU-WT cells were cultured in Neurobasal/DMEM-F12 mixture (1:1). Cells were cultured
for 24 h. At the end, the cell secretomes were collected for exosome isolation, characteriza-
tion, and inflamma-miRNA determination. Cells were also processed for morphological
and cellular dynamics, including miRNA content.
2.8. Evaluation of Cell Viability by the Nexin Assay
To determine the viability of adherent and floating cells, cells were collected from
the culture medium or detached with trypsin, mixed, and spun down at 500 g for 5 min.
Pellet was resuspended in 1% bovine serum albumin (BSA) in PBS and stained with
phycoerythrin-conjugated annexin V (Annexin V-PE) and 7-amino-actinomycin D (7-AAD),
using the Guava Nexin Reagent® (Merck Millipore). Stained cells were analyzed with a
flow cytometer (Guava easyCyte 5 HT, Merck Millipore), using the Guava Nexin Software.
Four cellular populations were distinguished: viable cells (Annexin V-PE and 7-AAD
double-negative), early apoptotic cells (Annexin V-PE positive and 7-AAD negative),
late apoptotic cells (Annexin V-PE and 7-AAD double-positive) and necrotic cells/cellular
debris (Annexin V-PE negative and 7-AAD positive).
2.9. Immunocytochemistry for Mitochondrial Fusion/Fission, Cytoskeletal and Synaptic Proteins
We evaluated the rates of mitochondrial fission and fusion by assessing the fission
dynamin-related protein 1 (DRP1) and mitofusin-2 (MFN-2), respectively. Additionally,
we determined the expression levels of synaptic proteins, e.g., the postsynaptic density
protein 95 (PSD-95) and the synaptic vesicle protein SV2 (SV-2). Lastly, we evaluated the
microtubule-associated proteins Tau and MAP-2, as well as the cytoskeleton-associated
F-actin patterns in dendrites and axons.
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Cells were plated onto coverslips and fixed with paraformaldehyde (4% w/v in PBS)
for 20 min. Then, cells were washed with PBS and permeabilized with Triton-X100 0.2%
in PBS for 10 min. Blocking was performed with BSA at 3% in PBS for 30 min. F-actin
was stained using phalloidin conjugated with AlexaFluor® 594 probe (1:100 in BSA 1%
in PBS). As primary antibodies, we used mouse anti-DRP1 (1:150), rabbit anti-MFN-2
(1:150) (AbCam, Cambridge, UK), mouse anti-PSD-95 (1:200) (Merck Millipore), rabbit
anti-Tau (1:1000), rabbit anti-SV-2 (1:1000) (Synaptic Systems) and rabbit anti-synapsin-1
(produced in-house). As secondary antibodies, we used goat anti-rabbit conjugated with
AlexaFluor488 (1:1000); goat anti-mouse conjugated with AlexaFluor488 (1:1000); goat
anti-mouse conjugated with ALexaFluor594 (1:1000) and goat anti-rabbit conjugated with
AlexaFluor405 (1:500) (Thermo Fisher Scientific). All antibodies were diluted in BSA 1%
in PBS. Coverslips were washed with PBS followed by 2 min incubation with Hoechst
33,258 dye (1:1000 in BSA 1% in PBS) for nuclear staining. The coverslips were quickly
immersed in methanol and mounted in DPX (Sigma-Aldrich). For widefield imaging,
we used a Zeiss AxioScope A1 microscope with an AxioCam HRm camera and 40×(air)
and 63×(oil) objectives.
2.10. Dendrite Extension, Ramification and Spine Density
Dendrite extension and ramification analysis was performed as stated in [37], using the
immunofluorescence detection of the cytoskeletal protein MAP-2, known to be located
mainly in dendrites and used widely as a neuritic marker. Cells previously plated onto
coverslips were fixed for 20 min with freshly prepared 4% paraformaldehyde in PBS
and then washed with PBS. This was followed by permeabilization with Triton-X-100
0.2% (Invitrogen) in PBS for 10 min and subsequent blocking with BSA at 3% in PBS for
30 min. Mouse anti-MAP-2 (1:100) was used as the primary antibody, and goat anti-mouse
conjugated with AlexaFluor488 (1:1000, Thermo Fisher Scientific) diluted in BSA 1% in
PBS was used as the secondary antibody. Coverslips were submerged in PBS for cleaning
and then incubated with Hoechst 33,258 dye (1:1000 in BSA 1% in PBS) (Sigma-Aldrich).
Then, coverslips were immersed in methanol and mounted in DPX Mountant (Sigma-
Aldrich). For dendrite analysis, fluorescence was visualized using the Zeiss AxioScope,
as mentioned above. Green-fluorescence images of ten random microscopic fields were
acquired per sample. Evaluation of dendrite length and ramification from individual
neurons was determined using ImageJ software in the NeuronJ plugin. Spines were
assessed by confocal imaging, in a Leica TCS SP8 inverted microscope with a 40×(oil)
immersion objective, sequential laser excitation at 405/488/552 nm and spectral detection
adjusted for the emissions Alexa Fluor 405/488/594, respectively. Multiple representative
images (1080 × 1080-pixel resolution) of at least 3 independent experiments were captured
from random microscopic fields. Number of cells, fluorescence area, fluorescence intensity,
and number of spines were measured using Fiji software tools [38].
2.11. Mitotracker Active Mitochondria Labeling
Cells were incubated for 30 min at 37 ◦C with 500 nM of MitoTracker Red CMXRos®,
according to the manufacturer’s instructions (Thermo Fisher Scientific), to stain viable
mitochondria, and then fixed with 4% (w/v) paraformaldehyde [11]. Cell nuclei were
stained with Hoechst 33,258 dye. Images were acquired as mentioned previously and
total fluorescence intensity (FI) of the Mitotracker Red was assessed using ImageJ soft-
ware. After all images were scaled, they were converted to black and white (B&W) images
(Image > Colour Threshold). FI and cell area were automatically measured using (Ana-
lyze > Analyze Particles) with the options “area” and “integrated intensity” selected from
the menu “set measurements”. Then, the FI of MitoTracker Red was normalized using the
calculated cell size (Supplementary Table S4). In total, over 320 cells were processed for
each treatment group.
Cells 2021, 10, 2424 8 of 27
2.12. Determination of Aβ1-40 and Aβ1-42 by ELISA
Equal volumes of cell supernatants were collected and immediately stored at−80 ◦C until
analysis. Aβ1-40 and Aβ1-42 release was quantified by sandwich ELISA assay, according
to the manufacturer’s instructions (IBL, Fujioka-Shi, Japan). Absorbance at 450 nm was
measured at room temperature in a GloMax microplate reader (Promega, Madison, WI, USA).
2.13. Statistical Analysis
Group comparisons between different cells/conditions were performed by one-way
ANOVA with Bonferroni post-hoc multiple comparisons test. Specific pair-wise compar-
isons were performed by two-tailed Student’s t-test assuming equal or unequal variances,
as appropriate. Statistical analysis was performed using GraphPad PRISM 8.0.1 software
(GraphPad Software Inc., San Diego, CA, USA), and only differences of p < 0.05 were
considered significant.
3. Results
3.1. SWE and PSEN AD Neuronal Models Show Upregulated miR-124, miR-125b and miR-21,
but Only miR-124 Is Shuttled from Both Mutated Cells into Their Exosomes
We started by confirming the elevated expression of inflammatory-associated miR-124,
miR-21, miR-125b, miR-155 and miR-146a in SH-SWE cells differentiated with RA and cultured
for 24 h (Figure 1A; at least p < 0.05), as we have previously shown in [15]. We observed that
such inflamma-miRNAs were indeed all significantly upregulated in these cells. Given the
advantage of iPSC-derived neurons in better mimicking the AD pathophysiology [39], we next
evaluated whether similar changes in those inflamma-miRNAs were present in the iPSC-
derived iNEU-PSEN cells from the AD patient, when compared with data from the healthy
iPSC-derived iNEU-WT cells. We found similarities between SH-SWE and iNEU-PSEN cells
for the elevation of miR-124, miR-125b and miR-21 (Figure 1A; at least p < 0.05).
Exosomes are implicated in the clearance and dissemination of AD pathogenic pro-
teins [40] and miRNAs, having a critical impact on the function of recipient cells [10].
Most of the miRNAs are passively released into exosomes, thus reflecting their cellular
expression [41]. However, exosomal miRNA content may be dictated by cell target re-
quirements, leading to either a selective retention of miRNAs or to the active release of
them. In the present study, exosomes were isolated from the cell secretomes and char-
acterized for their morphology by transmission electron microscopy (TEM) (Figure 1B),
as well as for usual protein markers by Western blot (Figure 1C). Exosomes showed a
round morphology, and we identified the cup shape of surface-desiccated exosomes in
high magnification, as well as the typical presence of ALIX, CD63 and Flotilin-1 proteins
(Figure 1C). Though exosomes were isolated from the same volume of cell supernatants
(each mL from 5 × 104 cells), the concentration of exosomes by TEM was apparently higher
in secretomes from the iNEU cells, either mutated or not. Accordingly, we found at least
2-fold enriched total RNA levels (ng/µL) in these cells, as compared with the SH-derived
ones (p < 0.01) (Supplementary Table S2), while total proteins (µg/µL in three pooled
samples) were at least 5-fold increased.
Representative histograms by NTA analysis of exosomes from SH-WT and SH-SWE
samples and from a single exploratory of those from iNEU-WT and iNEU-PSEN cells are
depicted in Figure 1D. The data are in line with the other described results indicating
that an enhanced number of exosomes are released by the iNEU cell lines, probably
derived from the stressful conditions of their generation [40], and eventually aggravated
by the presence of the PSEN mutation (1.7-fold elevation vs. respective WT; p < 0.05)
(Supplementary Table S2). Differences in the biogenesis of exosomes should be explored in
the future for a larger number of samples and extended to other iNEU cell lines derived
from other mutations. It is worth noting that some variation in exosome size distribution
profiles in the fresh collected samples was observed, though the most prevalent size in all
samples was near 100 nm, the most usual in exosomes. We cannot, however, disregard that
some aggregation processes may justify the appearance of peaks over 100 nm.
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Increased levels of miR-124 and miR-155 in exosomes were found independently of
the cell of origin (at least, p < 0.05), when compared with those from WT cells (Figure 1E).
Among all the miRNAs, miR-124 sorted out as the only one elevated in both cells and
exosomes in the two AD in vitro models. It is worth noting that miR-155 seems to be
selectively and actively shuttled from the iNEU-PSEN cells into exosomes, while its sorting
from SH-SWE cells appears to occur by a passive mechanism. Considering the consistent
elevation of miR-124 in both models and in their exosomes, we next explored the effects of
modulating miR-124 expression levels in each of the neuronal AD models.
3.2. Tansfection with miR-124 Mimic and Inhibitor Is Effective in Both AD Neuronal Models,
though iNEU Cells Show a Higher Resistance
miR-124 was described to have neurogenic and neural differentiation potential [30,42]
and to be required for the expression of homeostatic synaptic plasticity by miR-124 trans-
fection. Neuroblastoma cells [2], rat-derived neurospheres [43] and dental pulp stem
cells [44] were already used for miR-124 transfection. Specifically, the knockdown and
overexpression of miR-124 was earlier performed in differentiated SH-WT cells [45]. How-
ever, it is not clear from the literature whether such a treatment was already carried out in
iPSC-derived neurons.
Here, we used the miR-124 mimic and the miR-124 inhibitor in the SH-WT/SH-
SWE and iNEU-WT/iNEU-PSEN cells to overexpress and downregulate, respectively,
the intracellular levels of miR-124 (Figure 2). The controls included mock samples, as well as
“scramble” negative controls (NC) for the inhibitor and mimic, respectively, as schematically
represented in Figure 2A. Data for all the controls were like the miR-124 expression levels in
the non-treated cells depicted in Figure 1A, and between models, thus discarding artifactual
effects in the expression levels of miR-124 by the transfection process. Mock controls
reproduced the increased expression of miR-124 observed in the naïve SH-SWE and iNEU-
PSEN cells (Figure 2B; at least p < 0.05). Successful transfection for either inhibitor or
mimic in WT and mutated cells in both human AD models was achieved. Data obtained
with the inhibitor revealed that miR-124 downregulation was similarly attained in the
four cell types tested (at least 80% decrease, p < 0.01). However, levels of the transfection
efficiency with miR-124 mimic were dissimilar in each of the models. Improved transfection
efficiency was obtained in SH-WT and SH-SWE cells (29-fold increase and 70-fold increase,
respectively, p < 0.01), when compared with iNEU-WT and iNEU-PSEN cells, suggesting a
higher resistance of these cells to the treatment [46]. Here, we reached an overexpression
of ~17-fold in iNEU-WT and of ~12-fold in iNEU-PSEN cells. Therefore, we cannot rule
out that such differences in the overexpression levels for miR-124 modulation in each of
the two tested AD models may have had an impact on data obtained in cells and miRNA
dynamics with miR-124 inhibitor and miR-124 mimic, which will be presented below.
3.3. miR-124 Is an Inducer of Neurite Outgrowth and Mitochondria Activation in SH-SWE Cells
miR-124 has been indicated as a promising therapy in neurodegenerative disor-
ders [47] and to attenuate some AD pathological processes [48,49]. Its overexpression
in mouse P19 cells promoted neurite outgrowth, while the opposite was observed by
blocking miR-124 function [50]. Therefore, we first assessed the impact of miR-124 inhibitor
and miR-124 mimic on total dendrite length by using the MAP-2 immunostaining analysis
(Figure 3A). While no differences were observed in either iNEU-WT or iNEU-PSEN cells
(data not shown), a decrease in dendrite length was achieved by the transfection with the
miR-124 inhibitor in both SH-WT and SH-SWE cells (Figure 3B; p < 0.05). No changes were
found for the total dendrite length in SH-WT and SH-SWE cells between mock controls.
In contrast, an increase in total dendrite length was noticed by the modulation with the
miR-124 mimic, though only statistically significant in the mutated SH-SWE cells (p < 0.05).
Differences between non-modulated SH-WT and SH-SWE cells were only observed when
the primary dendrite length and the number of ramifications per cell were considered,
with a reduction, and an elevation, respectively, only in mutated cells, suggesting an asso-
ciated increased stress-related condition. The profile of primary dendrite length per cell
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upon treatment with the miR-124 modulators was like that of the total dendrite assessment
(decreased by the inhibitor, p < 0.01 in SH-WT and p < 0.05 in SH-SWE; elevated by the
mimic only in SH-SWE, p < 0.01). The branching of neurites increased with the inhibitor
(p < 0.05) and decreased with the mimic (p < 0.05) in SH-SWE, but not in SH-WT cells.
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Efficient mitochondrial function is necessary for neurite outgrowth [51]. To analyze
mitochondrial potential and location, we used MitoTracker-Red, a dye that selectively
accumulates in metabolically active mitochondria. At first glance, no significant differences
were found between the raw mean intensity per cell in each of the modulations performed
in SH-WT or SH-SWE cells (data not shown). However, when normalized to cell area
(data are provided in Supplementary Table S4), MitoTracker intensity was significantly
decreased in SH-SWE cells with the inhibitor and enhanced in both cell types with the
mimic (Figure 3C; p < 0.05), which led to visible MitoTracker staining dots in neuronal
projections (white arrowheads, Figure 3A). It is worth noting that, though no significant
differences were obtained, we found changes in cell area between the SH-WT and SH-SWE
treated with the mock, the inhibitor, and the mimic. However, in the case of SH-WT
cells, the increase in the Mitotracker intensity seems to not derive from the cell area,
but to be induced by the mimic, considering that the cell area in the mock-treated SH-
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WT cells (1037 µm2) are close to that of the same cells treated with the mimic (961 µm2)
(Supplementary Table S4). Therefore, though we cannot disregard the contribution of cell
area differences to Mitotracker Red intensity increase by the mimic, namely, in SH-SWE
cells, it cannot be considered the only responsible factor for the findings achieved.
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modulation of miR-124 with inhibitor and mimic, relatively to mock, in SH-WT and SH-S E cells.
Cells were obtained, differentiated, and transfected, as detailed in Material and Methods. (A) Repre-
sentative fluorescence images of MAP-2 (green) for dendrites, Mitotracker (red) for mitochondria,
and MFN-2 (green)/DRP-1 (red) for fusion/fission mitochondria dynamics. Cell nuclei are stained
with Hoechst 33,258 dye (blue). Mitochondrial clumps are seen in the neurites (white arrowheads).
(B) Evaluation of total dendrite length, primary dendrite length and primary dendrite number.
(C) Quantification of fluorescence intensities for Mitotracker Red, DRP-1 and MFN-2. Results are
mean ± SEM fold cha ge, from at least three independent experiments. * p < 0.05 and ** p < 0.01
vs. respec ive mock controls, one-way ANOVA with Bonferroni post-hoc test. # p < 0.05, between
the same treatment in SH-WT and SH-SWE cells, two-tailed student’s t-test. miR, miRNA; SH-WT,
human SH-SY5Y wild-type neurons; SH-SWE, human SH-SY5Y expressing the APP695 Swedish
mutant protein; iNEU-WT, iNeurons derived from induced pluripotent stem cells (iPSCs) generated
from a healthy control; iNEU-PSEN, iNeurons from iPSCs generated from a patient carrying the
PSEN1∆ E9 mutation; MAP-2, microtubule-associated protein 2; DRP1, protein dynamin-related
protein 1; MFN-2, mitofusin-2 protein; FI, fluorescence intensity.
Cells 2021, 10, 2424 13 of 27
Once mitochondria fusion and fission dynamics influence neuronal processes and
cell survival [52], we next assessed MFN-2 and DRP-1, two proteins implicated in such
processes [53,54]. The inhibitor of miR-124 did not cause any modification in mitochondria
fission dynamics (Figure 3C), whereas it caused an elevation of mitochondria fusion in
SH-SWE cells, probably to mitigate cell stress induced by the treatment (Figure 3A,C;
p < 0.05 vs. respective mock and WT cells). Additionally, when cells were assessed for
retrograde (dynein) and anterograde (kinesin family number 3A, KIF3A) axonal transport
proteins, miR-124 mimic enhanced the expression of both genes in SH-WT cells (at least
p < 0.05) and of KIF3A in iNEU-WT ones (data not shown). No changes in such processes
were noticed in either the mutated cells or in those treated with the miR-124 inhibitor.
It is worth adding that none of the miR-124 modulatory treatments altered cell viability
(Supplementary Figure S4).
3.4. miR-124 Expression Levels below a Certain Threshold Compromise Dendritic Spine Density in
iPSC-Derived iNeurons
Dendritic spine dysfunction is a critical feature in the pathogenesis of AD-associated
dementia [55]. Dendritic spines are specialized structures on neuronal processes whose loss
directly correlates with synaptic function failure [56]. Therefore, a better understanding of
the dendritic spine alterations may drive the success of therapeutic interventions in AD.
Dendritic morphogenesis and spine density were shown to be promoted by miR-124 in
mouse olfactory bulb neurons [57]. Here, we profit from having our iNEU-WT or iNEU-
PSEN cell models to explore the consequences of modulating miR-124 expression levels
on the number of dendritic spines that receive input from a synapse of another neuron,
since such an assessment cannot be realized in SH-SY5Y neuroblastoma cultures [58].
iNEU-maturated cells, presenting clear MAP-2 and Tau immunostainings, as well as
the synaptic proteins SV-2, synapsin and PSD-95 (Supplementary Figure S3), showed a
much higher morphological complexity than that of SH-WT and SH-SWE cells. When cells
were assessed for the spine density (Figure 4), no significant differences were observed
with the miR-124 mimic, relative to data on the mock control, though a slight elevation was
noticed. In contrast, the miR-124 inhibitor led to a significant reduction in the number of
dendritic spines, either in iNEU-WT (p < 0.01) or in iNEU-PSEN (p < 0.05) cells, suggesting
that it is important to sustain miR-124 expression levels within defined limits to hold
functional plasticity.
3.5. miR-124 Reduces APP Gene Expression, While It Differently Influences Aβ Oligomerization
and Tau Phosphorylation in Each of the Experimental AD Neuronal Models
The data obtained so far suggest that decreased levels of miR-124 induces a decrease in
neurite length and number of spines. BACE1 and Tau were found to be decreased in the
APP/PS1 mice after treatment with miR-124 [59], and biopsy samples from sporadic AD
patients revealed reduced levels of miR-124 and increased gene and protein expression of
BACE1 [8]. However, miR-124 was also found to be increased in the brains of AD patients
and in male Tg2576 transgenic mice [9]. Such discrepancies accounted for our interest in
investigating how the different expression levels of miR-124 could modify APP processing
and Tau hyperphosphorylation in our AD cell models. We started by characterizing such
AD hallmarks in the non-modulated cells. We observed an upregulation of the APP gene
expression in both mutated cells relatively to their matched WT controls (Figure 5A; p < 0.01).
miR-124 inhibitor induced an increase in the APP mRNA expression in the SH-WT cells
(p < 0.05), but not in any of the other cells. Most interestingly, the miR-124 mimic markedly
decreased APP mRNA levels in both SH-SWE (p < 0.05) and iNEU-PSEN (p < 0.01) cells.
Aβ oligomers are known to be increased in the early stages of AD and to attack
neurons [60], while also inducing Tau hyperphosphorylation [61], namely, at serine residues
396 and 404 [62], that contribute to microtubule and synapse dysfunctions [63]. The SH-
SWE cells revealed increased levels of the real toxic Aβ trimers/tetramers species (~20 kDa),
relatively to SH-WT cells, which were sustained by treatment with the miR-124 inhibitor
(Figure 5B,C; p < 0.05). Notoriously, miR-124 mimic was able to significantly reduce small
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Aβ oligomer formation, when compared with the mock control (p < 0.05). Oligomerization
was, however, different in iNEU-PSEN cells, where we observed a predominance of larger
oligomers (less neuroactive but can dissociate into small oligomers) that persisted with
each of the tested modulations (p < 0.05). However, no differences for the release of Aβ1-40
or Aβ1-42 from the mutated cells were observed, either before or after miR-124 modulation,
except for the enrichment of Aβ1-40 in the secretome from SH-SWE cells, as compared
with that from the SH-WT ones (Supplementary Figure S5; p < 0.05).
Next, Tau phosphorylation at the serine 404 site was evaluated. We could not detect
any basal difference in the phosphorylated Tau between WT and mutated samples of
each model, though the ratio between the phosphorylated Tau and the total one was near
1-fold in the neuroblastoma cells and 2-fold in the iPSC-derived neurons. Inhibition of
miR-124 was translated into an increase in such a ratio only in SH-WT cells vs. mock control
(Figure 5D,E; p < 0.05). Curiously, when we upregulated miR-124 with its mimic, the ratio
decreased to 1 only in iNEU-PSEN cells (p < 0.01), pointing to miR-124 benefits in decreasing
the amount of the phosphorylated Tau. Altogether, the data suggest that the upregulation
of miR-124 prevents some of the AD-associated risk factors.
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expression by RT-qPCR revealing a decrease in the mutated cells with the miR-124 inhibitor. (B) Rep-
resentative Western blots for Aβ species showing different representation and predominance of
bands at 120 and 20 kDa. (C) Quantification of small and large Aβ oligomers showing that the first
are increasingly represented in SH-SWE cells and the later in iNEU-PSEN cells. (D) Representative
Western blots for Tau phosphorylation status at serine 404. (E) Quantification of phospho-Tau/total-
Tau ratio revealing a decrease in iNEU-PSEN cells by the miR-124 mimic. Results are mean ± SEM
fold change from at least three independent experiments. * p < 0.05 and ** p < 0.01 vs. respective
mock controls, one-way ANOVA with Bonferroni post-hoc test. # p < 0.05 and ## p < 0.05, between
the same treatment in WT and mutated cells, two-tailed student’s t-test. miR, miRNA; SH-WT,
human SH-SY5Y wild-type neurons; SH-SWE, human SH-SY5Y expressing the APP695 Swedish
mutant protein; iNEU-WT, iNeurons derived from induced pluripotent stem cells (iPSCs) generated
from a healthy control; iNEU-PSEN, iNeurons from iPSCs generated from a patient carrying the
PSEN1∆E9 mutation.
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3.6. Neuron-to-Neuron Transfer of miR-124 Is More Effective among SH-SWE Cells Than between
SH-WT Cells
Considering the benefits of the upregulated miR-124 in reducing APP processing,
we wondered whether SH-WT and SH-SWE cells treated with miR-124 mimic would
transmit this miRNA to neighboring neurons. If so, that may have potential benefits on
using such a strategy to counteract AD pathological mechanisms. The shuttle of miRNAs
from cell-to-cell was already shown and suggested to be mediated by exosomes and vesicle-
free extracellular miRNAs [64]. In this regard, we decided to explore this issue using
SH-WT and SH-SWE cells in a non-cell-contact co-culture system (Figure 6). For that,
mock and miR-124 mimic transfected SH-WT as donor cells were co-cultured with matched
non-treated cells for 24 h. The same was performed with the SH-SWE cells. We noticed
that miR-124 expression in transfected SH-WT and SH-SWE donor cells decreased with the
time of coculturing (more than 60% after 24 h), by comparing the transfection efficiency in
Figure 6 with that previously obtained in monocultures (Figure 2). Despite the potential
transfer of the miR-124 into the secretome (as a soluble species or as part of the exosomal
cargo), and to the non-treated cells, we still observed increased levels of miR-124 in the
original donor cells relatively to mock controls (14-fold, p < 0.01) after the 24 h of incubation.
As expected, the co-culture of mock-treated SH-WT and SH-SWE cells with the respective
non-treated cells did not cause any change in their miR-124 expression.
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system after transfection of miR-124 in SH-WT and SH-SWE donor cells. Cells were obtained, dif-
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non-transfected matched cells (recipient) for 24 h. (A) Schematic representation of SH-WT and SH-
SWE donor cells transfected with mock and miR-124 mimic in co-culture with the matched non-
transfected recipient cells. (B) miR-124 expression levels in the transfected and non-transfected cells 
after 24 h of co-incubation. Quantification was obtained by RT-qPCR and results are mean ± SEM 
fold change from at least three independent experiments. ** p < 0.01 vs. mock and # p < 0.05 vs. cells 
modulated with miR-124 mimic, two-tailed student’s t-test. miR, miRNA; SH-WT, human SH-SY5Y 
wild-type neurons; SH-SWE, human SH-SY5Y expressing the APP695 Swedish mutant protein. 
3.7. Extracellular miRNA Signaling after Neuronal miR-124 Modulation with Its Mimic or 
Inhibitor Depends on the Cell Pathological Signature and Associated Mutation 
After confirming that miR-124 may disseminate from neuron to neuron, we explored 
the contribution mediated by exosomes and by the vesicle-free secretome in such propa-
gation. In fact, miRNAs can be present in non-exosomal free-floating species and com-
plexes, including in free Argonaut 2 complexes that account for more than 90% of all ex-
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may enrich or deplete the extracellular secretome cargo in miR-124 by up- or downregu-
lating its expression levels in donor cells. Efficiency was more notorious for the upregula-
tion of miR-124, namely, in the exosomal component, attesting its passive delivery from 
the transfected donor cells. 
Then, we investigated whether the transfection with miR-124 mimic and miR-124 in-
hibitor in SH-WT/SH-SWE and in iNEU-WT/iNEU-PSEN cells would have an influence 
on cellular and exosomal inflamma-miRNA signature (Figure 7B–D for the mutated cell 
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exosomes with both inhibitor and mimic (at least p < 0.05) (Figure 7B). Different responses 
Figure 6. miR-124 is transmitted from donor to recipient neurons in a non-cell-contact co-culture
system after transfection of miR-124 in SH-WT and SH-SWE donor cells. Cells were obtained, dif-
ferentiated, and transfected, as detailed in Material and Methods, before being co-cultured with
non-transfected matched cells (recipient) for 24 h. (A) Schematic representation of SH-WT and
SH-SWE donor cells transfected with mock and miR-124 mimic in co-culture with the matched non-
transfected recipie t cells. (B) miR-124 expression levels in the transfected and non-transfected cells
a ter 24 h of co-incubation. Quantificatio was obtained by RT-qPCR and results are mean ± SEM fold
change from at least three independent experiments. ** p < 0.01 vs. ock and # p < 0.05 vs. cells mod-
ulated with miR-124 mimic, two-tailed student’s t-test. miR, miRNA; SH-WT, human SH-SY5Y
wild-type neurons; SH-SWE, human SH-SY5Y expressing the APP695 Swedish mutant protein.
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Interestingly, a 5-fold upregulation of miR-124 in SH-WT naïve recipient cells was
obtained after being co-cultured with the miR-124 mimic transfected SH-WT donor cells
(p < 0.05 vs. mock transfected donor cells co-cultured with SH-WT naïve recipient cells),
though the transference corresponded to only 40% of the directed transfected cells (p < 0.01
vs. miR-124-transfected donor cells). The same was observed in SH-SWE cells, with a 3-fold
increase in the recipient cells, i.e., near 60% of that in donor cells transfected with miR-124
mimic (p < 0.01 vs. mock transfected donor cells co-cultured with SH-SWE non-transfected
recipient cells).
From these data, we believe that miR-124 is indeed transmitted from neuron to neuron,
though apparently with more efficiency in SH-SWE than in SH-WT cells, perhaps by easy
cell-to-cell propagation of miR-124 between mutated cells. Only future studies will confirm
if such a propensity is also true for other miRNAs.
3.7. Extracellular miRNA Signaling after Neuronal miR-124 Modulation with Its Mimic or
Inhibitor Depends on the Cell Pathological Signature and Associated Mutation
After confirming that miR-124 may disseminate from neuron to neuron, we explored
the contribution mediated by exosomes and by the vesicle-free secretome in such propaga-
tion. In fact, miRNAs can be present in non-exosomal free-floating species and complexes,
including in free Argonaut 2 complexes that account for more than 90% of all extracel-
lular miRNAs, or in exosomes [65,66]. As depicted in Figure 7A, the distribution of the
upregulated miR-124 in SH-WT, SH-SWE, iNEU-WT and iNEU-PSEN cells occurs by solu-
ble non-exosomal (at least p < 0.05, except for SH-WT cells) and exosomal dissemination
(p < 0.01 for all). It is also worth noting that miR-124 inhibition was similarly reflected by
its reduced levels in soluble and in exosomal fractions from the transfected SH-SWE cells
(p < 0.05) and in the iNEU-WT soluble fraction (p < 0.05). The results confirm that we may
enrich or deplete the extracellular secretome cargo in miR-124 by up- or downregulating
its expression levels in donor cells. Efficiency was more notorious for the upregulation
of miR-124, namely, in the exosomal component, attesting its passive delivery from the
transfected donor cells.
Then, we investigated whether the transfection with miR-124 mimic and miR-124
inhibitor in SH-WT/SH-SWE and in iNEU-WT/iNEU-PSEN cells would have an influ-
ence on cellular and exosomal inflamma-miRNA signature (Figure 7B–D for the mutated
cell responses to the modulation; Supplementary Table S5 for the WT cell responses to
the modulation).
Decreased miR-125b levels were generally observed in the mutated cells and in their
exosomes with both inhibitor and mimic (at least p < 0.05) (Figure 7B). Different responses
were obtained in WT cells and respective exosomes, since low levels were observed with the
miR-124 inhibitor (at least p < 0.05, except for SH-SWE exosomes), but increased ones with the
miR-124 mimic (p < 0.01, except for iNEU-WT cells), as depicted in Supplementary Table S5.
Relatively to miR-21, it behaved diversely in each of the AD cellular models upon the
modulation with the inhibitor. It increased in SH-SWE cells (p < 0.05) and was depleted in
exosomes (p < 0.01), pointing to an active retention by the cells, while it was decreased in
iNEU-PSEN cells (p < 0.01), without changes in the exosomal cargo. The miR-124 mimic
caused a depletion of miR-21 in both AD models, but only significant in iNEU-PSEN cells
(p < 0.01) and in their exosomes (p < 0.05). The representation of miR-21 in WT cells after
modulation with the miR-124 inhibitor (Supplementary Table S5) was the opposite of data
in the mutated cells, with no changes in the SH-WT cells, but a significant increase in the
iNEU-WT cells (p < 0.01), and similarly decreased exosomal levels. Inverse data were
obtained with the miR-124 mimic. It caused miR-21 upregulation in SH-WT cells and in
exosomes from both cell lines (at least p < 0.05).
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124 inhibitor and miR-124 mimic in the release of miR-124 into the secretome, as a soluble species 
and as a exosomal cargo. (B) Evaluation of cellular inflamma-miRNA expression levels after mod-
ulation of miR-124 with its mimic and inhibitor. (C) Evaluation of exosomal inflamma-miRNA ex-
pression levels after cellular modulation of miR-124 with its mimic and inhibitor. (D) Schematic 
representation of cellular and exosomal inflamma-miRNA distribution in the classical and in the 
advanced neuronal AD models by miR-124 inhibitor and miR-124 mimic. Results are mean ± SEM 
Figure 7. Transfection of SH-WT/SH-SWE and of iNEU-WT/iNEU-PSEN cells with miR-124 inhibitor
and miR-124 mimic influences iR-124 representation in the vesicle-free secretome (soluble) and
p ckaging into exosomes, while also mod fies th repr senta ion of other i flam a-miRNAs in the
same cells and respective exosomes. (A) Evaluation of the influence of the cell treatment with miR-124
inhibitor and miR-124 mimic in the release of miR-124 into the secretome, as a soluble species and as
a exosomal cargo. (B) Evaluation of cellular inflamma- iRNA expression levels fter modulation
of miR-124 with its mimic and inhibitor. (C) Evaluation of exosomal inflamma-miRNA expression
levels after cellular modulation of miR-124 with its mimic and inhibitor. (D) Schematic representation
of cellular and exosomal inflamma-miRNA distribution in the classical and in the advanced neuronal
AD models by miR-124 inhibitor and miR-124 mimic. Results are mean ± SEM fold change from at
least three independent experiments. * p < 0.05 and ** p < 0.01 vs. respective mock controls, one-way
ANOVA with Bonferroni post-hoc test. miR, miRNA; SH-WT, human SH-SY5Y wild-type neurons;
SH-SWE, human SH-SY5Y expressing the APP695 Swedish mutant protein; iNEU-WT, iNeurons
derived from induced pluripotent stem cells (iPSCs) generated from a healthy control; iNEU-PSEN,
iNeurons from iPSCs generated from a patient carrying the PSEN1∆E9 mutation.
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miR-146a was found to be upregulated in SH-SWE and iNEU-PSEN cells upon the
modulation with the miR-124 inhibitor (p < 0.01) (Figure 7B). However, it was only enriched
in exosomes from SH-SWE cells, once it was found to be depleted in those from iNEU-PSEN
cells (p < 0.01) (Figure 7C). The retention of miR-146a in these mutated cells may derive
from their specific requirements. In WT cells, the elevation of miR-146a by the miR-124
inhibitor was only observed in SH-WT cells (p < 0.05), and its presence in exosomes was
mostly reduced (Supplementary Table S5). A general decline upon the miR-124 mimic was
observed in the mutated cells and in their exosomes (at least p < 0.05, except for iNEU-PSEN
cells), as well as in the WT cells (at least p < 0.05), but then with an increased exosomal
representation (at least p < 0.05). These data suggest that cells manipulate the passive and
the selective release of miRNAs differently, in a target-dependent manner and accordingly
to specific pathological features.
Finally, miR-155 was unchanged by the miR-124 inhibitor in the mutated cells/exosomes.
However, we found its elevation in the WT cells and their exosomes (at least p < 0.05, Sup-
plementary Table S5), except in iNEU-WT cells, where a reduction was obtained (p < 0.01).
In turn, the miR-124 mimic led to a generalized reduction in miR-155 in the mutated and
WT cells/exosomes (p < 0.01, except for iNEU-PSEN and SH-WT cells), thus indicating a
preventive effect of the miR-124 mimic in miR-155-mediated neuroinflammation.
Other contrasting differences between the expression of inflamma-miRNA profiles
after mimic and inhibitor modulations in cells and exosomes were obtained when the
two-tailed Student’s t-test was used and are portrayed in Supplementary Table S5.
Given the pleiotropic differences in mRNA signaling obtained between WT and
mutated cells, with either inhibitor or mimic, together with their potential dependence
on models and cell mutations explored in the present study, we decided to summarize
the results in Figure 7D for clarity. Our results emphasize the highly dynamic network of
miRNA gene regulation and its dependence on the cell requirements to sustain homeostasis,
which varied with the genetic mutation and the experimental neuronal cell lines. Data also
support the benefits of miR-124 modulation in sustaining neuronal dynamics and balanced
miRNA signaling in AD and the use of iNeurons in modelling AD disease, though it
is worth highlighting that just a cell line was investigated, thus not representing the
heterogeneity of AD patients.
4. Discussion
Experimental models of AD are crucial to gaining better knowledge on the pathological
processes and to test the potential of new therapeutic approaches. However, in the case
of transgenic mice, the high failure rate in the translation of successful results into clinics
outlines their key limitations [31]. The use of human cell-based experimental models
surpasses the concerns associated to such species differences. Neuroblastoma cells are
one of the most widely used in vitro model of AD, though not fully reproducing Aβ and
Tau pathology [67]. Some of these flaws have been tentatively surpassed by using the
SH-SY5Y cell line overexpressing either WT human APP (APP695) or APP harboring the
Swedish double mutation (K670N/M671L) [68]. In conformity, here, we used such human
AD neuronal cells since they are cost-effective, easy to work, can be kept in culture for
long periods of time, are more precise, provide more material and bypass ethical concerns.
Interestingly, we have previously shown that these cells release Aβ1-40 [15] and may be
important to accelerating therapeutic drug discovery and saving money, before moving
to animal models or other more advanced systems to validate findings. Alternatively,
iPSCs started to be generated from patient fibroblasts, and the use of iPSCs-differentiated
neurons allowed for studies on sporadic and familiar cases of AD that better mimic the
pathological condition [69]. However, they also show some limitations, which are mostly
associated to a difficult recapitulation of cell ageing, phenotypic variation, and an absence
of interactions with glial cells, if not used in triculture cell types and 3D models. We can
expect that these constraints will be overcome in future studies using the direct conversion
of somatic cells [70].
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The modulation of miR-124 in the two different AD neuronal models has bene-
fits on the prevention of AD-associated pathological mechanisms, which may, however,
vary across the in vitro models and the human iPSC-derived neuronal lines from either
sporadic patients or presenting diverse mutations. In conformity, our study has limita-
tions by just using a control case and one iNEU-PSEN cell line, which may represent only
part of the AD spectrum. Nevertheless, our results underline some improvements by
the miR-124 upregulation and indicate that the most important will be to keep miR-124
levels between strict limits to sustain cell homeostasis and to adopt a modulatory strat-
egy that considers the patient miR-124 signature, thus contributing to a breakthrough in
personalized medicine.
The PSEN1 mutant iPSCs, from which we derived our iNEU-PSEN, manifested hall-
marks of AD pathology (increased Aβ production, oxidative stress and compromised
neurosupportive function) when differentiated into astrocytes [32]. Interestingly, when dif-
ferentiated into microglia, despite evidencing enhanced migration ability, the cells released
diminished levels of cytokines [33]. These authors evidenced heterogeneous microglia
phenotypes depending on whether they derived from iPSCs associated with the APOE4
genotype, or with the APPSwe and PSEN1 mutations, supporting that those microglia
impairments are somehow associated to the implicated mutations. Thus, we believe that
more pertinent findings can be obtained when combined experimental models are used
to address controversial issues, as is the case with miR-124 in AD pathogenicity. Actually,
miR-124 and its role in neuropathology is a hot topic with accumulating contradicting
reports of increased [9] and decreased [8] levels in AD, as well as different perspectives
about the protective or detrimental effects.
We hypothesize that such miR-124 inconsistencies derive from studies performed with
different experimental models, disease stages and brain regions [10]. In sum, these stud-
ies have not, so far, provided a clear idea on the role of miR-124 in the AD onset and
progression, nor if discrepancies that were found derive from functional neuronal differ-
ences among sporadic and familial AD patients, supporting the urgent need for reliable
biomarkers for predisposing susceptibilities and pathology staging.
The present study then used the SH-SWE cells, already explored by us in previous
studies [15] and the new iNEU-PSEN hippocampal neurons derived from iPSCs of an
AD patient based on stablished protocols [32,35]. In such prior work, we have found that
miR-124, miR-21 and miR-125b were upregulated in SH-SWE cells and their exosomes,
and that increased neuronal miR-124 contributed to its increased expression levels in
microglial cells, after 48 and 72 h of coculturing, leading to a decrease in the miR-124
target CCAAT/Enhancer-Binding Protein alpha (C/EBP-α) mRNA expression. However,
as far as we know, there are no data concerning the expression of such miRNAs in neurons
generated from iPSCs, mainly if considering the PSEN1 mutation. Moreover, the existing
studies on the miRNA role, namely, that of miR-124, in AD pathogenicity are not yet
consensual, as mentioned above.
Therefore, we assessed our set of inflammatory-associated miRNAs in SH-SWE cells
and their exosomes and compared with data from the same evaluation in iNEU-PSEN cells,
as well as from their respective controls SH-WT and iNEU-WT cells. We found the presence
of miR-124, miR-125b and miR-21 upregulations in both SH-SWE and iNEU-PSEN cells,
while in exosomes there was an increased representation of miR-124 and miR-155 in the
two mutated cell types. However, only miR-124 was consistently enriched in cells and
exosomes in both models, indicating a crucial role in neuronal function/dysfunction and
paracrine signaling. Our data are in line with other findings obtained in AD patients and
in the Tg2576 transgenic mice, where miR-124 was also found to be overexpressed [9,10].
Altogether, such findings enhanced our interest to explore the beneficial and detrimental
aspects of miR-124 expression levels in AD pathology in these two cell experimental models,
the SH-SWE and iNEU-PSEN cells and in their derived exosomes. For that, we decided to
overexpress and downregulate miR-124 by using its mimic and inhibitor. In this context,
our study was pioneering; miR-124 modulation in neurons had heretofore only been
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tested once in SH-SY5Y cells [45]. The transfection of cells resulted in the upregulation of
miR-124 by the mimic and downregulation by its inhibitor. Slightly higher resistance to
transfection by iNEU-PSEN cells relatively to SH-SWE may relate with a more difficult
process in primary and stem cells when compared with the “easier” efficiency achieved in
cell lines [71,72].
One of the known effects of miR-124 expression in neurons is to promote neurite out-
growth by regulating genes encoding proteins associated to cytoskeleton organization [50].
Such a finding was observed by the miR-124 mimic, mainly in the SW-SWE cells, but such
influence was not noticed in the INEU-PSEN cells. Curiously, miR-124, together with miR-9,
were shown to also increase dendritic complexity in cortical neurons obtained from embry-
onic mice [73]. We did not observe any modification in the SH-WT cells, while increased
ramification was noticed in the SW-SWE cells, either untreated or treated with the miR-124
inhibitor, returning to control levels with the miR-124 mimic. This is in accordance with the
role of miR-124 in suppressing variability in dendritic branching numbers [74]. Efficient
mitochondrial function is the basis for successful neurite outgrowth [51]. Increased red
fluorescence intensity of MitoTracker staining was observed following miR-124 mimic
transfection in either SH-WT or SH-SWE cells, probably to assure the enhanced length of
dendrites, a process that demands high energy [75]. It is worth noting, however, that apart
from the inhibitor-dependent enhanced fusion in SH-SWE cells, no significant changes were
noticed for DRP1, thus suggesting the absence of mitochondria structural abnormalities or
elevated cytosolic Ca2+ levels [76].
Synaptic failure is a cause of cognitive decline, and the loss of dendritic spines is
associated to synaptic dysfunction [56] and the pathological accumulation of Tau in AD [77].
In the present study, the loss of dendritic spines was evidenced by the miR-124 inhibitor
only in iNEU-WT and iNEU-PSEN cells once they could not be visualized in neuroblastoma
cultures [58]. Increased Tau phosphorylation was observed by the miR-124-inhibitor in
SH-WT cells, but its decrease was achieved by the mimic in iNEU-PSEN cells, suggesting
a potential beneficial effect in AD pathology, already proposed in a previous study [49].
In addition, data also show that iNEU-PSEN cells are a reasonable alternative AD model
to the transgenic mice to test strategies for attenuating Tau hyperphosphorylation and
support the relevance of sustaining miR-124 expression levels within defined margins,
as already proposed by other Authors [78]. We may also emphasize that the neuroblastoma
model is more satisfactory to evaluate impacts on dendrite outgrowth, while iPSC-derived
neurons are a better alternative for assessing dendritic spine impairments (Table 1).
Table 1. Comparative pathological characteristics of human SH-SWE and iNEU-PSEN neuronal AD models in research.
Pathological Hallmarks in Alzheimer’s Disease Models
















iNEU-PSEN PSEN1∆E9 Yes No Yes Yes Yes (largeoligomers) No Yes
SH-SWE, human SH-SY5Y expressing the APP695 Swedish mutant protein; iNEU-PSEN, neurons differentiated from induced pluripotent
stem cells generated from a patient carrying the PSEN1∆E9 mutation; APP, amyloid precursor protein; Aβ, amyloid-beta peptide.
APP upregulation is known to promote AD pathogenesis by favoring Aβ genera-
tion [79], which is still considered a primary pathological hallmark of AD [80]. Elevated
expression levels of APP was a common finding in the two AD human cell models here
used. At least in SH-SWE cells, we demonstrated that the reduction in miR-124 expres-
sion was translated into an increased APP mRNA level, thus promoting Aβ production
and emphasizing its detrimental outcome. It is worth highlighting, however, that the
upregulated expression of miR-124 when we used its mimic was particularly beneficial
in counteracting APP gene expression in the mutated cells, either in SH-SWE or in iNEU-
PSEN ones. This feature, again, validates the need for regulating miR-124 levels between
Cells 2021, 10, 2424 22 of 27
narrow thresholds when one considers the fact that BACE1 is a potential downstream
target of miR-124 [59]. Light Aβ species formed by trimers/tetramers were noticed in
the untreated SH-SWE cells, while the oligomeric Aβ species were predominant in the
iNEU-PSEN cells (Table 1). Both Aβ trimers/tetramers and oligomers are considered
neurotoxic species [81,82] and, though distinctly represented, were found in the differently
mutated cells.
In the past years, it was demonstrated that miRNAs are not only present intracellu-
larly, but are also detectable in substantial amounts extracellularly, including in biological
fluids, being present either in exosomes or as soluble components in the vesicle-free secre-
tome [83]. This horizontal transfer of miRNAs is part of autocrine and paracrine signaling
mechanisms involved in cell-to-cell communication and in the propagation of inflamma-
tory mediators, including miRNAs [11,84,85]. In this study, we have shown that SH-WT
and SH-SWE cells overexpressing miR-124 are responsible for its enhanced expression
in donor cells, when using a non-contact co-culture system, thus attesting the cell-to-cell
transfer of this miRNA [64]. To further explore this issue, we assessed the presence of
miR-124 in either the soluble part of the secretome or as part of the exosomal cargo when
released from SH-WT/SH-SWE and iNEU-WT/iNEU-PSEN cells treated with the miR-124
mimic. As expected, we identified miR-124 presence as a soluble and exosomal component,
when derived either from WT cells or from mutated ones. However, miR-124 was highly
enriched in exosomes from iNEU-PSEN cells comparatively to those from SH-SWE cells,
thus indicating its preferential exosomal package in such case. Though the favored loading
of specific miRNAs into exosomes was noticed for other miRNAs, such as miR-320 and
miR-150, the decision of the host cells for active or passive miRNA sorting processes into
exosomes remain a controversial issue [86]. When considering the effects exerted by the
intracellular miR-124 inhibitor in the respective exosomal cargo, one major difference
between the SH-SWE and the iNEU-PSEN cells was found for miR-146a expression levels.
While increased in both cell lines, its sorting was processed by a passive way in the first
case, while it was actively retained in iNEU-PSEN cells, probably due to its increased target
genes [41]. No major differences were observed between the action of the miR-124 inhibitor
or the miR-124 mimic on the expression of miR-125b, which was decreased in both cases.
Considering that miR-125b induces Tau hyperphosphorylation [87], one may consider
that both modulatory interventions may have benefits. Another interesting finding was
that miR-124 mimic led to a decrease in miR-155 and miR-146a in exosomes released by
either SH-SWE or iNEU-PSEN cells, contributing to a less inflammatory milieu considering
their role as pro-inflammatory mediators [10,88]. Indeed, deletion of miR-155 in mice was
shown to promote axon growth, to reduce neuroinflammation, as well as to enhance neuro-
protection and repair after injury [89]. Although having a dynamic expression during AD
progression, miR-146a inversely correlates with the receptor expression on myeloid cells 2
(TREM2) in patients with AD, which may impair microglia phagocytic ability [90]. Further
investigation using co-culture experiments will provide insights into the effects of modu-
lating neurons with miR-124 inhibitor and miR-124 mimic toward microglia polarization
into AD disease-associated phenotypes or into reparative subtypes.
5. Conclusions
Our study, by using SH-SWE (classical) and iNEU-PSEN (advanced) cells, was the first
to show mutation-independent increased neuronal levels of miR-124, miR-125b and miR-21
and of exosomal miR-124 and miR-155 in both AD models. Among all these intracellular
upregulated inflamma-miRNAs, only miR-124 was shuttled into exosomes in the two
experimental systems, thus suggesting having an autocrine/paracrine regulation role. Ad-
ditionally, and though deserving further research, we demonstrate that miR-124 inhibitor
largely compromises dendrite length and spines, enhances APP processing, and promotes
neuronal miR-146a-induced inflammation. In contrast, such effects are mostly counter-
acted by the miR-124 mimic, which increased the transmembrane mitochondrial potential,
reduced Tau hyperphosphorylation, as well decreased the exosomal cargo in miR-155 and
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miR-146a. The data suggest that miR-124 expression levels should then be strictly regulated
to exert a neuroprotective role. Besides the common findings of miR-124 modulation in SH-
SWE and iNEU-PSEN cells, different responsive profiles with its mimic and/or inhibitor
were observed, as highlighted in Table 1, which may relate to the mutation involved or be
directly associated to each of the AD neuronal models. These findings may help on the
decision to use SH-SWE and iNEU-PSEN cells depending on the studies intended to be
carried out. They also highlight that patient-specific inflamma-miRNA signatures support
the application of precision medicine principles in AD. Collectively, our data indicate that
miR-124 is a novel diagnostic biomarker in circulating exosomes and a potential thera-
peutic target in AD, whenever its deregulation is identified. Experiments in the future
using neuronal exosomes as vehicles to deliver exogenous miR-124 mimic or miR-124
inhibitor into microglia may contribute to also make these cells attractive for therapeutic
modulations in AD.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/cells10092424/s1, Table S1: Data on the healthy control and the Alzheimer’s disease (AD)
patient from which induced pluripotent stem cells (iPSCs) were generated and differentiated into
iNeurons that we used in this study, Table S2: Total RNA and protein concentrations in exosomes iso-
lated from SH-WT/SW-SWE and iNEU-WT/iNEU-PSEN neuronal cells, Table S3: List of primers used
for mRNA/miRNA analysis by RT-qPCR, Table S4: Expression profile of inflammatory-associated
miRNAs assessed by RT-qPCR in SH-WT and iNEU-WT cells, as well as in their exosomes, af-
ter transfection with miR-124-3p inhibitor and mimic, Figure S1: Schematic representation for the
differentiation of induced Pluripotent Stem Cells (iPSCs) into induced neurons (iNeurons), follow-
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